Clinical efficacy of CyberKnife stereotactic body radiation therapy for hepatic hilar cancer

Abstract

Objective To evaluate the efficacy and safety of CyberKnife stereotactic body radiation therapy (SBRT) in the treatment of hepatic hilar cancer. Methods A retrospective study was performed on the clinical data of 36 patients with hepatic hilar cancer who were admitted to our hospital and treated with CyberKnife SBRT from 2009 to 2015. In the 36 patients, 37 lesions were found with tumor diameters ranging from 1.5 to 5.5 mm (median diameter 3 cm). The Synchrony respiratory tracking system was used for 21 lesions in 20 patients, while the XSight spinal tracking system was used for 16 lesions in 16 patients. Local progression was evaluated based on contrast-enhanced computed tomography and/or magnetic resonance imaging. The Kaplan-Meier method was used to calculate local control (LC) and overall survival (OS) rates, and the log-rank test was used for survival comparison and univariate prognostic analysis. Results The median follow-up time was 12.7 months. The 1-and 2-year postoperative LC rates were 90% and 76%, respectively. The 1-year OS and progression-free survival (PFS) rates were 63% and 39%, respectively. The median OS and PFS times were 15.2 and 10 months, respectively. The incidence of grade 3 adverse reactions was 11%. Conclusions The CyberKnife SBRT is a safe and effective way to treat hepatic hilar cancer. Key words: Liver neoplasms/stereotactic radiotherapy; Stereotactic radiotherapy, CyberKnife; Treatment outcome